万维提示：

1、投稿方式：官网投稿

2、期刊网址：http://www.degruyter.com/view/j/labm

3、投稿网址：http://mc.manuscriptcentral.com/jlm

4、联系邮箱：JLM.editorial@deGruyter.com

5、信息说明：本刊信息来源于网络，包括 SCI 收录核心期刊，增补期刊，期刊收录数据每年进行更新。本站是公益性网站，为网友投稿提供免费服务，由于受相关约束，我们不能提供相关期刊的影响因子、JCR期刊分区等数据供大家参考，造成不便，敬请谅解。

LaboratoriumsMedizin-Journal of Laboratory Medicine

Information for Authors

1. Scope and general policies of the Journal

2. Ethical conduct of research

3. Submission of manuscripts

4. Preparation of manuscripts

5. Post-acceptance

1. Scope and general policies of the Journal

LaboratoriumsMedizin (Journal of Laboratory Medicine; JLM) is a bi-monthly published journal that reports on the

latest developments in laboratory medicine. Particular focus is placed on the integrative diagnostic aspects of the

clinical laboratory, but technical, regulatory, and educational topics are equally covered. The Journal specializes in

the publication of high-standard, competent and timely review articles on clinical, methodological and pathogenic

aspects of modern laboratory diagnostics. These reviews are critically reviewed by expert reviewers and JLM’s

Associate Editors who are specialists in the various subdisciplines of laboratory medicine.

JLM is issued bi-monthly, and it is published in print and electronically. The preferred publication langauge is

English, articles in German language are translated into English and published online only.

JLM offers the following article formats:

 Review and Mini Review – Systematic, narrative, and focused reviews. Review articles are normally

published by invitation, but suggestions to the Editors are welcome.

 Research Article – Reports of original research.

 Opinion Paper and Editorial

 Point/Counterpoint Paper

 Clinical Case Study-Mini Review

 Clinical Case Report

 Short Communication

 Letter to the Editor and Reply

 Guidelines and Recommendations

 Book Review

Submissions in the following fields are welcomed:

 Allergy and Autoimmunity

 Biobanking

 Clinical Chemistry and Metabolism

 Drug Monitoring and Toxicology

 Endocrinology

 Genetics

 Geriatric Laboratory

 Haematology

 Haemostasisiology

 Inflammation and Sepsis

 Laboratory Management

 Microbiology

 Neurological Laboratory

 Oncology

 Paediatric Laboratory

 POCT

 Transplantation- und Transfusion Medicine

 Virology

Peer review JLM is a single-blind journal. Manuscripts are reviewed anonymously by at least two independent

reviewers selected by the Editors.

Turnaround times JLM aspires to notify authors about the review decision within 3-4 weeks from submission date.

Revised manuscripts should be returned within 6 weeks. Accepted articles are published online within 4 weeks

after acceptance.

Rejection of manuscripts Manuscripts dealing with subjects that have been well studied in the literature, and that

do not resolve questions raised by previous studies, or manuscripts that are statistically underpowered, are likely to

be rejected without peer re-view. This applies in particular to studies of genetic associations, which will be

considered only if they contribute new insights and are statistically valid according to generally accepted criteria.

Articles which are likely to affect the choice, performance or interpretation of clinical tests will be favored over

those which do not, and animal or cell-culture studies need to justify their eligibility. Reporting of negative results

must be justified by prior evidence that a positive result would be expected. Manuscripts are also returned to

authors if they do not comply with the Information for Authors (e.g., if the number of words al-lowed for a certain

article type will be exceeded).

Unpublished material Submission of a manuscript to JLM implies that the work described has not been published

previously, except in the form of an abstract, academic thesis or lecture; that it is not under consideration for

publication elsewhere; that publication of the work is approved by all authors and tacitly or explicitly by the

responsible authorities where the work was carried out; and that, if accepted, it will not be published elsewhere, in

English, German, or in any other language, without the written consent of the Publisher.

2. Ethical conduct of research

For information on plagiarism, please refer to COPE Committee on Publication Ethics. Please note that JLM uses

the check program iThenticate to assess for potential overlap in prior publication(s). Any previously published

material must be referenced appropriately in the manuscript.

Informed consent The protection of privacy is a legal right that must not be infringed without individual informed

consent. In cases where the identification of personal information is necessary for scientific reasons, authors should

obtain full documentation of informed consent, including written permission from the patient or their legal

guardians prior to inclusion in the study. The following (or similar) statement should be included in the Materials

and methods section: Informed consent was obtained from all individuals included in this study.

Authorization for the use of human subjects Manuscripts containing information related to human use should

clearly state that the research complies with all relevant national regulations and institutional policies and has been

approved by the authors Institutional Review Board or any equivalent Committee. Copies of the guidelines and

policy statements must be available for review by the Managing Editor if necessary. The editors reserve the right to

seek additional information or guidance from reviewers on any cases in which concerns arise. All investigations

with human subjects must have been conducted by following the tenets of the Declaration of Helsinki, what is

more authors must identify the committee or review board approving the experiments, and provide a statement

indicating approval of the research. The following (or similar) statement should be included in the Methods section:

Ethical approval: The research related to human use has been complied with all the relevant national regulations,

institutional policies and in accordance the tenets of the Helsinki Declaration, and has been approved by the

authors institutional review board or equivalent committee.

Authorization for the use of experimental animals Manuscripts containing information related to animals use

should clearly state that the research has complied with all relevant national regulations and institutional policies

and has been approved by the authors institutional review board or equivalent committee. Copies of the

guidelines and policy statements must be available for review by the Managing Editor if necessary. The editors

reserve the right to seek additional information or guidance from reviewers on any cases in which concerns arise.

The research using animal subjects should be conducted according to the Principles of Laboratory Animal Care and

similar documents (e.g. NIH). For manuscripts reporting experiments on live vertebrates or higher invertebrates,

authors must identify the committee approving the experiments, and must confirm that all experiments were

performed in accordance with relevant regulations. The following (or similar) statement should be included in

the Methods section: Ethical approval: The research related to animals use has been complied with all the

relevant national regulations and institutional policies for the care and use of animals.

If the manuscript does not contain any study that requires human or animal ethical approval, the following

statement should be included in the Methods section: Ethical approval: The conducted research is not related to

either human or animals use.

Conflict of interest and author contributions A conflict of interest for a given manuscript exists when a participant

in the peer review and publication process – author, reviewer, and editor – has ties to activities that could

inappropriately influence his or her judgment, regardless of whether judgment is, in fact, affected. Financial

relationships with industry (for example, employment, consultancies, stock ownership, honoraria, expert

testimony), either directly or through immediate family, are usually considered the most important conflicts of

interest. However, conflicts can occur for other reasons, such as financial support of the study, ties

to health insurance, politics or other stakeholders, personal relationships, academic competition, and intellectual

passion.

To ensure fair and objective decision-making, authors must declare any associations that pose a conflict of interest

(financial, personal or professional) in connection with the manuscript under evaluation. This must be declared

during the submission process and also at the end of the the manuscript. If you have no declaration to make,

please insert None declared. The below mentioned statement should be included before the Reference section (or

after the Acknowledgments section, if applicable). Authors must also declare responsibility for the entire content of

the manuscript and may declare individual contributions of each author, if applicable.

Acknowledgments: (If applicable).

Author contributions: All the authors have accepted responsibility for the entire content of this submitted

manuscript and approved submission.

Research funding: Declaration or None declared.

Employment or leadership: Declaration or None declared.

Honorarium: Declaration or None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and

interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

Copyright Manuscripts are accepted on condition of transfer of copyright (for U.S. government employees: to the

extent transferable) to the publisher. Once the manuscript has been accepted, it may not be published elsewhere

without the consent of the copyright holders.

Note for authors of NIH-funded research De Gruyter acknowledges that the author of a US-agency-funded article

retains the right to provide a copy of the final manuscript to agency upon acceptance for publication or thereafter,

for public archiving in PubMed Central 12 months after publication in JLM. Note that only the accepted author’s

version of the manuscript, not the PDF file of the published article, may be used for NIH archiving.

3. Submission of manuscripts

Please submit manuscripts exclusively online at:

https://mc.manuscriptcentral.com/jlm

4. Preparation of manuscripts

Language Manuscripts should be written in clear and concise English (German). Please have your text proofread by

a native speaker or prefessional language service before you submit it for consideration. At proof stage, only minor

changes other than corrections of printers’ errors are allowed.

Cover letter Each manuscript should be accompanied by a cover letter containing a brief statement by the authors

describing the novelty and importance of their research.

General format and length Type the manuscript (including table legends, figure legends and references) doublespaced

using 12 pt font size and 1 inch margins. Number all pages. Do not use footnotes in the text, use

parentheses instead.

When you submit your work, please ensure the following:

 The manuscript is complete and uploaded correctly. (The HTML version and the PDF file generated from

the submitted files must be approved.)

 The title page contains the full title, short title, the full names of all authors (personal name, middle

initials, family name), and the full address and the academic title of the corresponding author. The title

page should also report the word count, the number of tables and figures, and whether the submission

includes any supplemental material.

 All Figures and Tables have been uploaded and appear correctly at the end of the PDF.

 Abstract, Keywords, List of Abbreviations, Tables and Figures, and captions and legends are included.

 A Brief Summary consisting of no more than up to 3 sentences and up to 60 words is included. This

Summary will be published in the Table of Contents as initial introduction to the article.

 Manuscript is spell-checked and within the word limit for the type of article.

 References are in the correct format (Vancouver style) and cited sequentially in the text.

 References mentioned in the reference list are cited in the text and vice versa.

 Ethical approval is obtained and mentioned in the text.

 Numbers in the text, tables, or figures use decimal points, not commas.

 Supplier names, incl. city and country, are provided for reagents and apparatus reported in the

manuscript.

General format and length of the types of articles accepted for submission

Article Category Word count Word count in

abstracta

Number of

keywords

Number of Tables

Figures

Number of

references

Review Article 6000 200, unstructered

or structuredb

3-6 8 150

Mini Review 3500 200, unstructered

or structuredb

3-6 4 40

Research Article 3500 250, structuredc

3-6 8 50

Opinion Paper 3500 250, unstructered

or structuredb

3-6 2 40

Point

Counterpoint

1500 200, unstructured 3-5 2 15

Clinical Case StudyMini

Review

3500 200, unstructered

or structuredd

3-5 4 40

Case Report 1500 Unstructured 3-5 4 15

Short

Communication

1500 200, structureda

3-5 4 15

Letter to the Editor

Reply

1200 n/a 3-5 2 10

Guidelines and

Recommendations

3500 250, unstructured 3-6 6 40

Editorial 1500 n/a n/a 1 10

a

Plus Brief Summary of up to 3 sentences/up to 60 words .

b

Background, Content, Summary and Outlook. c

Background,

Methods, Results, Conclusions. d

Background, Case, Summary and Outlook.

Studies dealing with diagnostic accuracy: Please refer to the 2015 Standards for Reporting of Diagnostic Accuracy

checklist (STARD).

Systematic Reviews and Meta-Analyses of randomized controlled trials: Please refer to the Preferred Reporting

Items for Systematic Reviews and Meta- Analyses statement (PRISMA). Authors must include a suitable PRISMA

flow chart in their submission. The flow diagram depicts the flow of information through the different phases of a

systematic review. A template of the PRISMA flow diagram is available here as a PDF and Word document.

References Adhere strictly to the reference style of the Journal (Vancouver; recommendations of the “International

Committee of Medical Journals Editors see Reference Style). All references mentioned in the Reference list must

be mentioned in the text, and vice versa. List and number the references consecutively in the order that they

appear in the text, including Tables and Figures. In the text, identify references by Arabic numerals in

[parentheses]. Italic and boldface font type in the Reference section is not allowed. List all authors; if the number is

7 or more, list the first 6 names followed by et al. Identify authors by last name first, followed by up to 2 initials,

without periods, indicating the authors’ first name. Only the first name of the title is capitalized, as well as proper

names within the title. Journal names are abbreviated as indicated in PubMed and in the Web of Knowledge

(NIH.Linkout.Journals; Web of Knowledge), without periods. After the abbreviated journal name, give the year of

publication, followed by a semicolon, volume number (but no issue number), followed by a double colon, and the

page numbers, with the last page number in shortened format. Meeting abstracts may be cited only if published in

journals. Unpublished observations and personal communications are cited only in the text. Correct linking of the

references depends on strict adherence to Journal style.

 Articles in journals: Haeckel R, Gurr E, Keller T. Permissible measurement uncertainty in the lower part of

measurement intervals. J Lab Med 2016;40:271-6.

 Articles in journals with 7 or more authors: Ma X, Luo Y, Wang J, Zhang L, Liang Y, Wu Y et al. Comparison

of student perception and performance between case-based learning and lecture-based learning in a

clinical laboratory immunology course. J Lab Med2016;40:283-9.

 Editorial: Klein H-G, Holdenrieder S. The role of cell-free nucleic acid diagnostics in clinical chemistry and

pathology. [Editorial] J Lab Med 2016;40:291-2.1881-2.

 Letter to the Editor: Weykamp C, Kuypers A, Bakkeren D, Franck P, Loon Dv, Gunnewiek JK, et al.

Creatinine, Jaffe, and glucose: another inconvenient truth [Letter]. Clin Chem Lab Med. 2015;53:e347-9.

 Supplements: Ploder M, Schroecksnadel K, Spittler A, Neurauter G, Roth E, Fuchs D. Moderate

hyperhomocysteinema in trauma and sepsis indicates poor survival. Clin Chem Lab Med

2009;47:Suppl:S187.

 Books and Monographs: Kahn CR, Weir GC, editors. Joslin’s diabetes mellitus, 13th ed. Philadelphia: Lea

and Febiger, 1994:1068.

 Chapters in Books: Karnofsky DH, Burchenal JH. The clinical evaluation of chemotherapeutic agents in

cancer. In: Macleod CM, editor. Evaluation of chemotherapeutic agents. New York: Columbia University

Press, 1949:191–205.

 Website: World Health Organization. WHO information for laboratory diagnosis of pandemic (H1N1) 2009

virus in humans update. Available at:

 http://www.who.int/csr/resources/publications/swineflu/WHO_Diagnostic_RecommendationsH1N1_200

90521.pdf. Accessed: 6 Nov 2009.

Tables Number Tables consecutively using Arabic numerals. Provide a short descriptive title, column headings, and

(if necessary) footnotes to make each Table self-explanatory. In the footnote, refer to information within the Table

with superscript lowercase letters, and do not use special characters or numbers. Separate units with a comma and

use parentheses or square brackets for additional measures (e.g., %, range, etc). Refer to Tables in the text as Table

1, etc. Use Table 1 (boldface), etc. in the title of the Table.

Figures

General requirements: All illustrations must be of reproduction-ready quality. They will be reduced in size to fit,

whenever possible, the width of a single column. Lettering of all Figures within the article should be uniform in

style (preferably a sans serif typeface like Helvetica) and of sufficient size (ca. 10 pt.). Uppercase letters A, B, C, etc.

should be used to identify parts of multi-part Figures. In the legend, these letters are included in parentheses. Cite

all Figures in the text in numerical order. Indicate the approximate placement of each Figure. Do not embed Figures

within the text body of the manuscript.

Halftone figures and line drawings: Figures should have a minimum resolution of 300 dpi (halftone figures) and

1200 dpi (line drawings) and be of good contrast. Faint shading may be lost upon reproduction. When drawing bar

graphs, use patterning instead of grayscales.

Color plates: Authors are encouraged to submit illustrations in color if necessary for the scientific content of their

work. Publication of color Figures is provided free of charge both in online and print editions.

Figure legends: Provide a short descriptive title and a legend, either below the Figure, in the main text, or on

separate pages, to make each Figure self-explanatory. Explain all symbols used in a Figure. Remember to use the

same abbreviations as in the text body.

Videos: Authors are encouraged to submit videos accompanying the article as Supplemental Material.

Supplemental material You may submit Supplemental material, i.e. additional tables, figures, videos, appendices or

other additional material (e.g. references) that exceeds the limitation of the article and/or illustrates the contents

of your article. Supplemental material should be uploaded as separate file(s) during submission. Within the text,

Supplemental material must be cited consecutively and be referred to as Supplemental material (e.g. see

Supplemental Material, Figure 1, or Supplemental Figure 1). Supplemental material is subject to peer review as part

of the manuscript. If the manuscript is accepted and the Supplemental material is posted online, it will be

referenced in the article of the printed version together with the URL where it can be found.

Nomenclature Follow the rules of the IUPAC-IUB Commission on Biochemical Nomenclature, as indicated in IUB

Biochemical Nomenclature and Related Documents. Enzyme names should be in accordance with the

recommendations of the IUPAC-IUB Commission on Biochemical Nomenclature, 1978, as in Enzyme

Nomenclature, published by Academic Press, New York, 1992. Genotypes should be given in italics, phenotypes

should not be italicized. Indicate the gene symbol and gene name as approved by the HUGO Gene Nomenclature

Committee. Nomenclature of bacterial genetics should follow Damerec et al. Genetics 1966; 54:61–76 (Damerec et

al.).

Permissions It is the authors’ responsibility to obtain permission to reproduce original or modified material that has

been previously published elsewhere.

5. For authors interested in Open Access publication

If your manuscript is accepted, open access publication is available for authors who wish to make their article freely

available on De Gruyter Online. Authors choosing to publish open access pay an article processing charge. All

articles undergo peer review and will be accepted for publication based on the quality of their scientific

contribution. Choosing open access publication has no influence on the peer review or acceptance process. For

more information on De Gruyter’s open access policies please visit:

http://www.degruyter.com/dg/page/577/open-access-policy

6. Post-acceptance

Proofs The corresponding author of an article will receive the proofs in electronic form to check for editing and

type-setting accuracy. Major changes to the article as accepted for publication will not be considered at this stage,

unless the authors pay for these changes.

Offprints The electronic files of typeset articles in Adobe Acrobat PDF format are provided free of charge;

corresponding authors receive an e-mail notification that their article has been published online. Paper offprints

can be ordered in addition; an offprint order form will accompany the page proofs and should be completed and

returned with the corrected proofs immediately if offprints are requested.

Please contact the Editorial Office with any further questions: Heike Jahnke, T: +49 30 26005-220, F: +49 30

26005-325, E-mail: JLM.editorial@deGruyter.com